Text Size

Glucose in Dialysis Water in Non-Diabetics

This study has been completed.
Sponsor:
Information provided by:
Regional Hospital Holstebro
ClinicalTrials.gov Identifier:
NCT00439023
First received: February 20, 2007
Last updated: September 14, 2007
Last verified: September 2007
History of Changes
  Purpose

The purposes are

  1. to measure the effect of dialysis with glucose on blood pressure, pulse rate, plasma concentration of glucose, plasma concentrations of glucagon, growth hormone, renin, angiotensin II, endothelin and body temperature, and
  2. to analysis the relationship between changes in blood pressure on the one hand and changes in vasoactive hormones on the other

Condition Intervention Phase
Renal Failure, Chronic
 Procedure: dialysis with glucose in dialysis water
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Glucose in Dialysis Water on Blood Pressure and Vasoactive Hormones in Dialysis Patients

Resource links provided by NLM:

Drug Information available for: Dextrose
U.S. FDA Resources

Further study details as provided by Regional Hospital Holstebro:

Primary Outcome Measures:
  • Effect of glucose in dialysis water on blood pressure, insulin and vasoactive hormones [ Time Frame: one week ]

Secondary Outcome Measures:
  • Relationship between changes in blood pressure and changes in hormones during treatment [ Time Frame: one week ]

Enrollment: 18
Study Start Date: May 2006
Study Completion Date: May 2007
Detailed Description:

Measurement of hormones and blood pressure during dialysis treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age > 18 years,
  2. Both men and women,
  3. Dialysis treatment for at least three months

Exclusion Criteria:

  1. Heart failure,
  2. Chronic liver disease,
  3. Diabetes mellitus,
  4. Malignant disease,
  5. Nephrotic syndrome,
  6. Lack of compliance, 7 Unwillingness to participate
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00439023

Locations
Denmark
Holstebro Hospital
Holstebro, Denmark, 7500
Sponsors and Collaborators
Regional Hospital Holstebro
Investigators
Study Chair: Erling B Pedersen, Professor Regional Hospital Holstebro
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00439023     History of Changes
Other Study ID Numbers: MED.RES.2007.01.EBP
Study First Received: February 20, 2007
Last Updated: September 14, 2007
Health Authority: Denmark: The Regional Committee on Biomedical Research Ethics

Keywords provided by Regional Hospital Holstebro:
Chronic renal failure, dialysis, hemodialysis,

Additional relevant MeSH terms:
Kidney Failure, Chronic
Renal Insufficiency
Renal Insufficiency, Chronic
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on May 19, 2013